PRCT·PROCEPT BioRobotics Corporation
PRCT|Analyst Targets
PRCT|Insider Trading
PRCT|Fundamentals
PRCT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $-0.25 | - | - |
| Q3'26 | $-0.39 | $-0.46 | -16.5% |
| Q3'25 | $-0.42 | $-0.38 | +9.8% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $118M | - | - |
| Q3'26 | $105M | $98M | -6.0% |
| Q3'25 | - | $83M | - |
PRCT|Monthly Returns
Market Data
PRCT Stock Snapshot
- Market cap
- 1.24B
- Day range
- $20.27 – $20.27
- News sentiment
- 58/100 · Neutral
- Analyst target
- $26.67 (+31.6%)
- Consensus
- Hold · 22 analysts
The trend on PRCT is bearish, and its momentum ranks in the lower part of DailyIQ's universe. Company-specific news dominates here; sector-level flows matter less than for larger names.
Behaviour On Record
What PRCT's own history says about today's numbers
- Realized volatility (21d)
- 74.9% 80th pct
- Below its peak
- -79.9%
- vs 200-day average
- -13.6%
- Up days (1y)
- 45%
PROCEPT BioRobotics Corporation is currently running 74.9% annualised volatility over the last 21 sessions. Measured against PRCT's own 5 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 54.5%.
PRCT is trading -79.9% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -37.4%, and the deepest was -68.5% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits -13.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 44th percentile — close to the gap it normally carries. Over the past year PRCT closed higher on 45% of sessions, and it is currently 1 session into a falling streak.
On November specifically: over 5 years of records, PRCT finished the month higher 2 of 5 times, with a median return of -6.9% and an average of -0.2%. Its strongest month historically has been May at +7.5% on average, its weakest June at -8.1%.
Overnight risk is measurable too: PRCT has opened more than 2% away from the prior close in 193 of 1,291 sessions (14.9% of the time), with the largest gaps running +15.4% and -7.7%.
All figures computed from 1,292 daily closes between 2021-09-15 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against PRCT's own 5-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of PRCT's sector?
PROCEPT BioRobotics Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, PRCT ranks 2nd of 15 tracked industries, leading.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 73
- Industry rank
- #2 of 15
Analyst Consensus Estimates
What do analysts expect PRCT to earn?
Analysts expect PROCEPT BioRobotics Corporation to earn -$1.68 per share in the fiscal year ending Dec 2026 and -$1.17 in the fiscal year ending Dec 2027, from 12 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Analyst Rating Changes
Are analysts turning bullish or bearish on PRCT?
Barclays most recently initiated coverage on PROCEPT BioRobotics Corporation to Overweight on Oct 7, 2026 with a price target of $30. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Barclays: Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Corporate Stakes
Which companies own a stake in PRCT?
Johnson & Johnson reports a stake in PROCEPT BioRobotics Corporation on SEC Form 13F: 357.9K shares, about 0.58% of the company, worth $6.5M at the end of Q3 2026. At today's price that stake is worth $7.3M, about 0.00% of JNJ's own market value.
- Holder
- JNJ
- Shares held
- 357.9K
- Stake
- 0.58%
- Value
- $6.5M
| Holder | Last quarter | Shares | % of PRCT | Value at filing | Value now | Change |
|---|---|---|---|---|---|---|
| Johnson & Johnson JNJ | 357.9K | 0.58% | $6.5M | $7.3M | +11.3% |
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
Earnings Release, Scored
What did PROCEPT BioRobotics Corporation's latest earnings release say?
Most important lines
- 1
“Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027.
New this quarter - 2
We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”
New this quarter - 3
The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
New this quarter
ETF holders
ETFs holding PRCT
Top ETF holdersWeight
News & sentiment
What is the news saying about PRCT?
PRCT rose 13.8% over the month to Nov 5. News tone held between 0 and 70 from Oct 6 to Oct 8, then jumped to 58 on Oct 12.
- Oct 14 -8.6%
- Oct 22 +9.0%
- Nov 4 +7.4%same day: PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Technical analysis
How strong is PRCT's momentum right now?
On the daily chart PRCT ranks at the 4th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling PRCT?
47 of the 74 tracked managers added to PRCT in their latest 13F and 22 trimmed. Together they own 32.8% of the company, worth $445.7M. BNP Paribas Asset Management Holding S.A. and Vanguard Portfolio Management alone hold 8.7%.
- $63.8M positionTrimmed 8.6% last quarter
- $57.1M positionAdded 4.4% last quarter
- $55.6M positionAdded 2.6% last quarter
- 4State Street Corp2.64%$36.5M positionAdded 5.7% last quarter
- 5Federated Hermes, Inc.2.05%$28.3M positionAdded 618.6% last quarter
- 6Fiera Capital Corp1.27%$17.5M positionTrimmed 19.9% last quarter
- 7LMR Partners LLP1.18%$16.3M positionNew position last quarter
- $11.8M positionAdded 19.2% last quarter
- $11.3M positionAdded 3.5% last quarter
- $10.8M positionAdded 4.5% last quarter
Discover more
How has PRCT done against its peers?
Over the six months to Nov 5, PRCT returned −19.5%. Of the 15 related stocks and ETFs, 14 did better, led by BDX at +48.1%.
- 1BDXBecton, Dickinson and Companyup 48.1%+67.6 pts
- 2DXCMDexCom, Inc.up 42.2%+61.7 pts
- 3GEHCGE HealthCare Technologies Inc.up 37.3%+56.8 pts
- 4MDTMedtronic plcup 34.8%+54.3 pts
- 5ZBHZimmer Biomet Holdings, Inc.up 29.5%+49.0 pts
- 6XLVHealth Care Select Sector SPDR Fundup 27.3%+46.8 pts
- 7WSTWest Pharmaceutical Services, Inc.up 26.6%+46.1 pts
- 8EWEdwards Lifesciences Corporationup 21.7%+41.2 pts
- 15PRCTThis stockdown 19.5%
- 16BSXBoston Scientific Corporationdown 20.6%−1.1 pts
